Cushing’s Syndrome Pipeline Market Review, H1 2018

The latest Pharmaceutical and Healthcare disease pipeline guide Cushing's Syndrome Pipeline Market Review, H1 2018, provides an overview of the Cushing's Syndrome (Metabolic Disorders) pipeline landscape, Company involved and drug profiles.

July 12, 2018 /MarketersMedia/ —

Cushing syndrome occurs due to abnormally high levels of the hormone cortisol. The most common cause is overuse of corticosteroid medications. Symptoms of this condition are obesity, glucose intolerance, muscle weakness, bone loss, cognitive dysfunction, depression, and increased urination. Other causes include a pituitary gland tumor and ectopic ACTH syndrome. Treatment includes surgery and medications to control excessive production of cortisol.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Cushing's Syndrome Pipeline Market Review, H1 2018, provides comprehensive information on the therapeutics under development for Cushing's Syndrome (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Cushing's Syndrome - Companies Involved in Therapeutics Development:
- Angion Biomedica Corp
- AstraZeneca Plc
- Corcept Therapeutics Inc
- Diurnal Group Plc
- ElexoPharm GmbH
- Hybrigenics SA
- Millendo Therapeutics Inc
- Novartis AG
- Orphagen Pharmaceuticals Inc
- Reset Therapeutics Inc
- Strongbridge Biopharma plc

Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1553677

The Cushing's Syndrome (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cushing's syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 5 and 2 respectively.

Cushing's Syndrome (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Order a Copy of this Research Report at http://www.reportsnreports.com/purchase.aspx?name=1553677

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cushing's Syndrome (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Cushing's Syndrome (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cushing's Syndrome (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cushing's Syndrome (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cushing's Syndrome (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cushing's Syndrome (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cushing's Syndrome (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contact Info:
Name: Hrishikesh Patwardhan
Email: [email protected]
Organization: ReportsnReports
Address: 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001
Phone: + 1 888 391 5441

Source URL: https://marketersmedia.com/cushings-syndrome-pipeline-market-review-h1-2018/376781

For more information, please visit http://www.reportsnreports.com/reports/1553677-cushings-syndrome-pipeline-review-h1-2018.html

Source: MarketersMedia

Release ID: 376781